Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis
Purpose Dupilumab is a widely recommended treatment for moderate-to-severe atopic dermatitis (AD), with known ocular side effects but less frequent cutaneous reactions.Material and methods This case report details a 52-year-old female patient with atopic dermatitis treated with dupilumab. After an i...
Saved in:
Main Authors: | C. Grote, F. Zirkenbach, J. N. Wagner, M. Augustin |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2025-12-01
|
Series: | Journal of Dermatological Treatment |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2025.2452987 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Eosinophilic esophagitis in the “atopic march”: dupilumab as an “umbrella” strategy for multiple coexisting atopic diseases
by: Nicola Lutzu, et al.
Published: (2025-01-01) -
Effectiveness and Safety of Dupilumab and Tralokinumab for Treating Atopic Dermatitis and Pruritic Skin Disorders in Oncological Patients: A Narrative Review
by: Lauletta G, et al.
Published: (2025-01-01) -
Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study
by: Filip Rob, et al.
Published: (2025-12-01) -
Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
by: Tiago Torres, et al.
Published: (2024-04-01) -
Moscatilin inhibits vascular calcification by activating IL13RA2-dependent inhibition of STAT3 and attenuating the WNT3/β-catenin signalling pathway
by: Tingting Zhang, et al.
Published: (2025-02-01)